Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
This study is currently recruiting patients.
Sponsored by: | National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
Purpose
This study will compare the effectiveness of anti-HIV drug regimens with or without a protease inhibitor (PI) in HIV infected adolescents. It will also determine if monitoring drug levels and adjusting the dose as necessary improves the effectiveness of these regimens.
Condition | Treatment or Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Efavirenz + 2 NRTIs Drug: Lopinavir/Ritonavir + 2 NRTIs Procedure: Therapeutic Drug Monitoring |
Phase III |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring
Expected Total Enrollment: 240
HIV infected adolescents may have a significantly higher capacity for immune reconsitution following highly active antiretroviral therapy (HAART). Despite this advantage, HIV infected adolescents are often reluctant to get proper medical care, follow through with doctor appointments, and adhere to medication schedules and regimens necessary to keep the infection under control. Lopinavir/ritonavir, a PI, and efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI), both have long half-lives that make them ideal drugs for the adolescent population, as they are more forgiving if patients miss or sleep through doses. This study will examine the effectiveness of two HAART regimens, one with the protease inhibitor lopinavir/ritonavir and two nucleoside reverse transcriptase inhibitors (NRTIs), and the other with the NNRTI efavirenz and two NRTIs. The efficacy of therapeutic drug monitoring (TDM) and subsequent dose adjustment will also be assessed with both regimens.
Patients will be enrolled in this study for 96 weeks (slightly less than 2 years) and will be randomly assigned into one of two groups. Group 1 will receive lopinavir/ritonavir and 2 NRTIs; Group 2 will receive efavirenz and 2 NRTIs. All patients will be independently and simultaneously randomly assigned to receive either TDM with subsequent dose adjustment if necessary or no TDM or dose adjustment. Patient medical history and physical exam will be conducted at screening, entry, and Weeks 2, 4, 16, 32, 40, 48, 60, 72, 84, and 96. Blood work will be completed at screening, entry, and Weeks 2, 4, 8, 16, 24, 32, 40, 48, 60, 72, 84, and 96. Self-reported pill counts and MEMS TrackCap readings (on lopinavir/ritonavir and efavirenz bottles) will be noted at Weeks 2, 4, 16, 32, 48, 60, 72, 84, and 96. Adherence Questionnaire Modules 1 and 2 will be given to patients at selected visits.
Patients enrolled in PACTG 390 (Different Combination Regimens and Treatment-Switching Guidelines in HIV Infected Children 18 Years of Age and Younger) are encouraged to co-enroll simultaneously in this study and in PACTG 219C (Long-Term Effects of HIV Exposure and Infection in Children).
Eligibility
Ages Eligible for Study: 13 Years - 23 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location and Contact Information
More Information
Click here for more information about efavirenz
Click here for more information about lopinavir/ritonavir
Click here for more information about nucleoside reverse transcriptase inhibitors [NRTIs]
Haga clic aquí para ver información sobre este ensayo clínico en español.
Publications
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |